

Table A1. Sensitivity analyses of direct comparisons: Dabigatran studies*

DABIGATRAN VERSUS ENOXAPARIN	Base case (random effects)	Fixed effects
	RR (95% CI)	RR (95% CI)
Symptomatic venous thromboembolism	0.71 [0.23, 2.12]	0.88 [0.55, 1.41]
Clinically relevant bleeding	1.12 [0.94, 1.35]	1.13 [0.94, 1.35]
Net clinical endpoint	0.93 [0.63, 1.37]	0.97 [0.74, 1.28]

*All studies scored 5 points in Jadad scale, were phase III and each of the studies had equal duration of prophylaxis in treatment arms. Therefore, only the sensitivity analysis according to statistical model assumption was conducted.

CI = confidence interval; RR = relative risk.

Table A2. Sensitivity analyses of direct comparisons: Rivaroxaban studies

RIVAROXABAN VERSUS ENOXAPARIN	Base case (random effects)	Fixed effects	Excluding studies < 5 score points in the Jadad scale*	Excluding phase II studies	Only studies with equal duration of prophylaxis**
	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)	RR (95% CI)
Symptomatic venous thromboembolism	0.48 [0.31, 0.75]	0.46 [0.31, 0.70]	0.46 [0.30, 0.70]	0.43 [0.27, 0.67]	0.54 [0.34, 0.85]
Clinically relevant bleeding	1.25 [1.05, 1.49]	1.26 [1.07, 1.49]	1.24 [1.03, 1.51]	1.26 [1.06, 1.49]	1.26 [1.00, 1.60]
Net clinical endpoint	0.88 [0.70, 1.12]	0.89 [0.72, 1.10]	0.87 [0.70, 1.08]	0.88 [0.69, 1.11]	0.93 [0.71, 1.22]

*Excluding the proof-of-concept study

**Equal duration in both treatment arms: Excluding RECORD2

CI = confidence interval; RR = relative risk.

Table A3. Sensitivity analyses of direct comparisons: Apixaban studies*

APIXABAN VERSUS ENOXAPARIN	Base case (random effects)	Fixed effects	Excluding phase II**
	RR (95% CI)	RR (95% CI)	RR (95% CI)
Symptomatic venous thromboembolism	0.82 [0.41, 1.64]	0.92 [0.57, 1.49]	0.93 [0.45, 1.93]
Clinically relevant bleeding	0.82 [0.69, 0.98]	0.82 [0.70, 0.98]	0.80 [0.65, 1.00]
Net clinical endpoint	0.92 [0.68, 1.23]	0.92 [0.68, 1.23]	0.91 [0.67, 1.23]

*All studies scored 5 points in Jadad scale, and each of them had equal duration of prophylaxis in treatment arms

**APROPOS study

CI = confidence interval; RR = relative risk.

Table A4. Sensitivity analyses of direct comparisons: Rivaroxaban studies, accepting the exclusion of major wound bleedings in the RECORD studies as per study publication

RIVAROXABAN VERSUS ENOXAPARIN	RR (95% CI)	p-value
Major bleeding	1.55 (0.86 to 2.80)	0.15
Net clinical endpoint	0.68 (0.50 to 0.91)	0.01

CI = confidence interval; RR = relative risk.